






Highlights of This Issue 1

SMALL MOLECULE THERAPEUTICS

- 3** **6 α -Acetoxyanopterin: A Novel Structure Class of Mitotic Inhibitor Disrupting Microtubule Dynamics in Prostate Cancer Cells**
 Claire Levrier, Martin C. Sadowski, Anja Rockstroh, Brian Gabrielli, Maria Kavallaris, Melanie Lehman, Rohan A. Davis, and Colleen C. Nelson
- 16** **TAS-116, a Novel Hsp90 Inhibitor, Selectively Enhances Radiosensitivity of Human Cancer Cells to X-rays and Carbon Ion Radiation**
 Younghyun Lee, Shigeaki Sunada, Hirokazu Hirakawa, Akira Fujimori, Jac A. Nickoloff, and Ryuichi Okayasu
- 25** **Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei**
 Magnus T. Dillon, Holly E. Barker, Malin Pedersen, Hind Hafsi, Shreerang A. Bhide, Kate L. Newbold, Christopher M. Nutting, Martin McLaughlin, and Kevin J. Harrington
- 35** **Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer**
 Chengfei Liu, Cameron M. Armstrong, Wei Lou, Alan Lombard, Christopher P. Evans, and Allen C. Gao
- 45** **Identification and Validation of Compounds Selectively Killing Resistant Cancer: Delineating Cell Line-Specific Effects from P-Glycoprotein-Induced Toxicity**
 András Füredi, Szilárd Tóth, Kornélia Szabéni, Veronika F.S. Pape, Dóra Türk, Nóra Kucsma, László Cervenak, József Tóvári, and Gergely Szakács
- 57** **N-Arachidonoyl Dopamine Inhibits NRAS Neoplastic Transformation by Suppressing Its Plasma Membrane Translocation**
 Min Wu, Jinyan Huang, Jianming Zhang, Cyril Benes, Bo Jiao, and Ruibao Ren
- 68** **ASP5878, a Novel Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing Hepatocellular Carcinoma**
 Takashi Futami, Hidetsugu Okada, Rumi Kihara, Tatsuya Kawase, Ayako Nakayama, Tomoyuki Suzuki, Minoru Kameda, Nobuaki Shindoh, Tadashi Terasaka, Masaaki Hirano, and Sadao Kuromitsu

- 76** **Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma**
 Amro Aboukameel, Irfana Muqbil, William Senapedis, Erkan Baloglu, Yosef Landesman, Sharon Shacham, Michael Kauffman, Philip A. Philip, Ramzi M. Mohammad, and Asfar S. Azmi
- 88** **Combinatorial Drug Screening Identifies Ewing Sarcoma-specific Sensitivities**
 Branka Radic-Sarikas, Kalliopi P. Tsafou, Kristina B. Emdal, Theodore Papamarkou, Kilian V.M. Huber, Cornelia Mutz, Jeffrey A. Toretsky, Keiryn L. Bennett, Jesper V. Olsen, Søren Brunak, Heinrich Kovar, and Giulio Superti-Furga
- 102** **The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737**
 Cécile Pétigny-Lechartier, Charlene Duboc, Abdelghani Jebahi, Marie-Hélène Louis, Edwige Abeillard, Christophe Denoyelle, Pascal Gauduchon, Laurent Poulain, and Marie Villedieu

LARGE MOLECULE THERAPEUTICS

- 116** **Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates**
 Patrick J. Burke, Joseph Z. Hamilton, Scott C. Jeffrey, Joshua H. Hunter, Svetlana O. Doronina, Nicole M. Okeley, Jamie B. Miyamoto, Martha E. Anderson, Ivan J. Stone, Michelle L. Ulrich, Jessica K. Simmons, Erica E. McKinney, Peter D. Senter, and Robert P. Lyon
- 124** **Establishment of the *In Vivo* Efficacy of Pretargeted Radioimmunotherapy Utilizing Inverse Electron Demand Diels-Alder Click Chemistry**
 Jacob L. Houghton, Rosemary Membreno, Dalya Abdel-Atti, Kristen M. Cunanán, Sean Carlin, Wolfgang W. Scholz, Pat B. Zanzonico, Jason S. Lewis, and Brian M. Zeglis
- 134** **Preclinical Efficacy of an Antibody-Drug Conjugate Targeting Mesothelin Correlates with Quantitative ⁸⁹Zr-ImmunoPET**
 Anton G.T. Terwisscha van Scheltinga, Annie Ogasawara, Glenn Pacheco, Alexander N. Vanderbilt, Jeff N. Tinianow, Nidhi Gupta, Dongwei Li, Ron Firestein, Jan Marik, Suzie J. Scales, and Simon-Peter Williams

Table of Contents

CANCER BIOLOGY AND SIGNAL TRANSDUCTION

- 143** **MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer**
Madeleine J. Oudin, Lucie Barbier, Claudia Schäfer, Tatsiana Kosciuk, Miles A. Miller, Sangyoon Han, Oliver Jonas, Douglas A. Lauffenburger, and Frank B. Gertler
- 156** **Interference with the HSF1/HSP70/BAG3 Pathway Primes Glioma Cells to Matrix Detachment and BH3 Mimetic-Induced Apoptosis**
Patrick Antonietti, Benedikt Linder, Stephanie Hehlhans, Iris C. Mildenerberger, Michael C. Burger, Simone Fulda, Joachim P. Steinbach, Florian Gessler, Franz Rödel, Michel Mittelbronn, and Donat Kögel
- 169** **Digitalis-like Compounds Facilitate Non-Medullary Thyroid Cancer Redifferentiation through Intracellular Ca²⁺, FOS, and Autophagy-Dependent Pathways**
Marika H. Tesselaar, Thomas Crezee, Herman G. Swarts, Danny Gerrits, Otto C. Boerman, Jan B. Koenderink, Hendrik G. Stunnenberg, Mihai G. Netea, Johannes W.A. Smit, Romana T. Netea-Maier, and Theo S. Plantinga
- 182** **Simvastatin-Induced Apoptosis in Osteosarcoma Cells: A Key Role of RhoA-AMPK/p38 MAPK Signaling in Antitumor Activity**
Walied A. Kamel, Eiji Sugihara, Hiroyuki Nobusue, Sayaka Yamaguchi-Iwai, Nobuyuki Onishi, Kenta Maki, Yumi Fukuchi, Koichi Matsuo, Akihiro Muto, Hideyuki Saya, and Takatsune Shimizu
- 193** **Pharmacological Inhibition of Myocardin-related Transcription Factor Pathway Blocks Lung Metastases of RhoC-Overexpressing Melanoma**
Andrew J. Haak, Kathryn M. Appleton, Erika M. Lisabeth, Sean A. Misk, Yajing Ji, Susan M. Wade, Jessica L. Bell, Cheryl E. Rockwell, Merlin Airik, Melanie A. Krook, Scott D. Larsen, Monique Verhaegen, Elizabeth R. Lawlor, and Richard R. Neubig
- 205** **Penfluridol Represses Integrin Expression in Breast Cancer through Induction of Reactive Oxygen Species and Downregulation of Sp Transcription Factors**
Erik Hedrick, Xi Li, and Stephen Safe

- 217** **Trifluoperazine, a Well-Known Antipsychotic, Inhibits Glioblastoma Invasion by Binding to Calmodulin and Disinhibiting Calcium Release Channel IP₃R**
Seokmin Kang, Jinpyo Hong, Jung Moo Lee, Hyo Eun Moon, Borami Jeon, Jungil Choi, Nal Ae Yoon, Sun Ha Paek, Eun Joo Roh, C. Justin Lee, and Sang Soo Kang

COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

- 228** **HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib**
 Michael F. Press, Catherine E. Ellis, Robert C. Gagnon, Tobias J. Grob, Marc Buyse, Ivonne Villalobos, Zhiyong Liang, Shafei Wu, Yung-Jue Bang, Shu-Kui Qin, Hyun Cheol Chung, Jianming Xu, Joon Oh Park, Krzysztof Jeziorski, Karen Afejar, Yanling Ma, Monica C. Estrada, Douglas M. Robinson, Stefan J. Scherer, Guido Sauter, J. Randolph Hecht, and Dennis J. Slamon
- 239** **Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers**
Arvind Arora, Swetha Parvathaneni, Mohammed A. Aleskandarany, Devika Agarwal, Reem Ali, Tarek Abdel-Fatah, Andrew R. Green, Graham R. Ball, Emad A. Rakha, Ian O. Ellis, Sudha Sharma, and Srinivasan Madhusudan

MODELS AND TECHNOLOGIES

- 251** **Enhanced Oncolytic Activities of the Telomerase-Specific Replication-Competent Adenovirus Expressing Short-Hairpin RNA against Dicer**
Mitsuhiro Machitani, Fuminori Sakurai, Keisaku Wakabayashi, Masashi Tachibana, Toshiyoshi Fujiwara, and Hiroyuki Mizuguchi



 **AC icon indicates Author Choice**
For more information please visit www.aacrjournals.org

Table of Contents

ABOUT THE COVER

By decoupling the targeting vector from the radioactivity at the time of injection, pretargeting strategies offer an enticing way to combine the exquisite selectivity and affinity of mAbs with the favorable pharmacokinetics of small molecules. In this issue, Houghton and colleagues report the development of a strategy for pretargeted radioimmunotherapy (PRIT) based on the extraordinarily rapid and bioorthogonal inverse electron demand Diels-Alder reaction between tetrazine (Tz) and *trans*-cyclooctene (TCO). The authors report that PRIT using a ^{177}Lu -labeled Tz radioligand (^{177}Lu -DOTA-PEG₇-Tz) and a TCO-bearing immunoconjugate of the CA19.9-targeting antibody 5B1 (5B1-TCO) resulted in a dose-dependent reduction in tumor volume in a murine model of pancreatic ductal adenocarcinoma. See article (beginning on p. 124) for more information.



Molecular Cancer Therapeutics

16 (1)

Mol Cancer Ther 2017;16:1-259.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/16/1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/16/1>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.